
US clinical-stage biotech firm Boston Pharmaceuticals has appointed Dr Craig Basson as its chief medical officer.
Dr Basson was previously global head of translational medicine (cardiovascular and metabolism) at Novartis (NOVN: VX) for 10 years, where he co-led the cardiovascular metabolism (CVM) disease area decision board, oversaw the leadership of early clinical portfolio through proof-of-concept (PoC) and supported late phase clinical programs by indication expansion PoC studies and specialized clinical pharmacology and profiling studies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze